Welcome to our dedicated page for Bridgebio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BridgeBio Pharma, Inc. filings document a commercial-stage biopharmaceutical company focused on medicines for genetic conditions, including financial results, product revenue disclosures, program updates, and formal reports on ATTR-CM, LGMD2I/R9, and achondroplasia development programs.
Its SEC record includes Form 8-K disclosures for results of operations, Regulation FD presentations, clinical and regulatory press releases, material agreements, an at-the-market equity distribution agreement, convertible senior notes, and a board-authorized stock repurchase program. Proxy materials address director elections, executive compensation votes, auditor ratification, incentive plan share reserves, governance structure, and stockholder voting matters.
BridgeBio Pharma (BBIO): Director insider sales reported. On 10/29/2025, a director reported multiple open‑market sales by the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 under a Rule 10b5‑1 plan adopted on August 28, 2024. Transactions included blocks of 111,755 and 43,393 shares, among others, at weighted average prices ranging from $65.4764 to $69.2358. Following the reported sales, 679,979 shares were beneficially owned indirectly by the trust.
BridgeBio Pharma (BBIO): Director transaction reported. A director executed a Rule 10b5-1 planned sale of 1,641 shares of common stock on 10/27/2025 at $65 per share. Following the sale, reported beneficial ownership stands at 878,338 shares held indirectly by the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 and 83,275 shares held directly. The 10b5-1 plan was adopted on August 28, 2024.
BridgeBio Pharma (BBIO): Director transaction reported. A director executed a Rule 10b5-1 planned sale of 1,641 shares of common stock on 10/27/2025 at $65 per share. Following the sale, reported beneficial ownership stands at 878,338 shares held indirectly by the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 and 83,275 shares held directly. The 10b5-1 plan was adopted on August 28, 2024.
BridgeBio Pharma (BBIO) reported Q3 2025 results as it scales commercialization of acoramidis (Attruby/Beyonttra). Total revenues were $120.7 million, driven by net product revenue $108.1 million, plus license and services revenue of $8.3 million and royalty revenue of $4.3 million. Loss from operations was $145.2 million. Net loss attributable to common stockholders was $182.7 million (basic and diluted net loss per share $0.95).
Operating expenses reflected launch build-out: research and development was $112.9 million, selling, general and administrative was $137.6 million, and restructuring, impairment and related charges were $8.8 million. Cash and cash equivalents were $642.9 million as of September 30, 2025. The balance sheet shows 2031 Notes, net, of $564.1 million, 2029 Notes, net, of $740.4 million, and 2027 Notes, net, of $546.5 million. Deferred royalty obligations, net, were $836.1 million.
Year-to-date, total revenues were $347.9 million with product revenue of $216.4 million. U.S. accounted for 89.6% of Q3 revenues. The company notes approvals for acoramidis across the U.S., EU, Japan and the UK supporting the commercial ramp.
BridgeBio Pharma (BBIO) reported Q3 2025 results as it scales commercialization of acoramidis (Attruby/Beyonttra). Total revenues were $120.7 million, driven by net product revenue $108.1 million, plus license and services revenue of $8.3 million and royalty revenue of $4.3 million. Loss from operations was $145.2 million. Net loss attributable to common stockholders was $182.7 million (basic and diluted net loss per share $0.95).
Operating expenses reflected launch build-out: research and development was $112.9 million, selling, general and administrative was $137.6 million, and restructuring, impairment and related charges were $8.8 million. Cash and cash equivalents were $642.9 million as of September 30, 2025. The balance sheet shows 2031 Notes, net, of $564.1 million, 2029 Notes, net, of $740.4 million, and 2027 Notes, net, of $546.5 million. Deferred royalty obligations, net, were $836.1 million.
Year-to-date, total revenues were $347.9 million with product revenue of $216.4 million. U.S. accounted for 89.6% of Q3 revenues. The company notes approvals for acoramidis across the U.S., EU, Japan and the UK supporting the commercial ramp.
BridgeBio Pharma, Inc. reported that it issued a press release titled “BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1.” The disclosure was made in connection with a current report and the press release is attached as Exhibit 99.1.
The company’s common stock trades on the Nasdaq Global Select Market under the symbol BBIO. The report is dated October 29, 2025 and was signed by the President and Chief Financial Officer. Investors can refer to Exhibit 99.1 for the full press release text.
BridgeBio Pharma, Inc. reported that it issued a press release titled “BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1.” The disclosure was made in connection with a current report and the press release is attached as Exhibit 99.1.
The company’s common stock trades on the Nasdaq Global Select Market under the symbol BBIO. The report is dated October 29, 2025 and was signed by the President and Chief Financial Officer. Investors can refer to Exhibit 99.1 for the full press release text.
BridgeBio Pharma, Inc. furnished a press release reporting recent business updates and financial results for the third quarter ended September 30, 2025. The release was provided as Exhibit 99.1 to an Item 2.02 Form 8-K dated October 29, 2025. The company noted that the information in Item 2.02, including Exhibit 99.1, is being furnished and not filed under the Exchange Act.
BridgeBio Pharma, Inc. furnished a press release reporting recent business updates and financial results for the third quarter ended September 30, 2025. The release was provided as Exhibit 99.1 to an Item 2.02 Form 8-K dated October 29, 2025. The company noted that the information in Item 2.02, including Exhibit 99.1, is being furnished and not filed under the Exchange Act.
BridgeBio Pharma (BBIO) filed a Form 8-K announcing it issued a press release titled “BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study.” The press release is furnished as Exhibit 99.1 and is incorporated by reference. This 8-K provides notice of the clinical update; detailed results are contained in the attached exhibit.
BridgeBio Pharma LLC, together with BridgeBio Pharma, Inc., reported acquiring 784,720 shares of BridgeBio Oncology Therapeutics, Inc. (BBOT) common stock on 10/10/2025 under transaction code J.
The shares were issued pursuant to an amendment to the Transition Services Agreement dated August 11, 2025, in exchange for additional financial and accounting support services provided through December 31, 2025.
After the transaction, 14,589,846 shares were beneficially owned. The shares are held by BridgeBio Pharma LLC, with voting and investment power exercised by its parent, BridgeBio Pharma, Inc. The reporting persons and directors disclaim beneficial ownership except to any pecuniary interest. The reporting person is identified as a director, and the form was filed by more than one reporting person.
BridgeBio Pharma, Inc. (BBIO) reported insider sales by Chief Executive Officer and Director Neil Kumar under a Rule 10b5-1 plan. The filing shows multiple market sales on 10/08/2025 and 10/09/2025, totaling 223,090 shares disposed at weighted-average prices in the mid-$54 range. Shares sold were held indirectly through two trusts for which the reporting person is a co-trustee; the report disclaims beneficial ownership except for any pecuniary interest. The transactions were reported on a Form 4 and signed by an attorney-in-fact on 10/10/2025.
BridgeBio Pharma, Inc. (BBIO) submitted a Form 144 notice for a proposed sale of 120,000 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $6,506,400, scheduled approximately on 10/08/2025 and to be executed on NASDAQ. The shares were acquired on 03/26/2016 in a conversion of management incentive units. The filer disclosed multiple prior 10b5-1 sales over the past three months from related trusts and an individual, with individual trade sizes typically of 20,000 shares and one sale of 26,156 shares, generating proceeds in the $0.92M–$1.28M range per transaction.
The filing includes the standard Rule 144 representation that the seller does not possess undisclosed material adverse information and notes reliance on written trading plans where applicable.
BridgeBio Pharma, Inc. form 144 shows a proposed sale of 120,000 common shares with an aggregate market value of $6,506,400, to be executed approximately on 10/08/2025 on NASDAQ. The shares were acquired on 03/26/2016 via conversion of Management Incentive Units. The filing lists the total shares outstanding as 191,168,504. Recent disclosed transactions show multiple 10b5-1 sales by related trusts and an individual (including Kumar Haldea Revocable/Family Trusts and Neil Kumar) across 08/07/2025–09/05/2025, totaling 186,156 shares sold in the past three months. The filer certifies no undisclosed material adverse information and notes the 10b5-1 representation where applicable.